MAYER, Jiří, Christopher ARTHUR, Jacques DELAUNAY, Grzegorz MAZUR, Xavier G. THOMAS, Agnieszka WIERZBOWSKA, Farhad RAVANDI, Erhan BERRAK, Mark JONES, Yuhan LI a Hagop M. KANTARJIAN. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. BMC Cancer. London: BioMed Central, 2014, roč. 14, č. 69, s. 1-9. ISSN 1471-2407. doi:10.1186/1471-2407-14-69.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics
Autoři MAYER, Jiří (203 Česká republika, garant, domácí), Christopher ARTHUR (36 Austrálie), Jacques DELAUNAY (250 Francie), Grzegorz MAZUR (616 Polsko), Xavier G. THOMAS (250 Francie), Agnieszka WIERZBOWSKA (616 Polsko), Farhad RAVANDI (840 Spojené státy), Erhan BERRAK (840 Spojené státy), Mark JONES (840 Spojené státy), Yuhan LI (840 Spojené státy) a Hagop M. KANTARJIAN (840 Spojené státy).
Vydání BMC Cancer, London, BioMed Central, 2014, 1471-2407.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Velká Británie
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 3.362
Kód RIV RIV/00216224:14110/14:00075094
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1186/1471-2407-14-69
UT WoS 000332490000001
Klíčová slova anglicky Decitabine; Acute Myelocytic Leukemia; Elderly; Treatment
Štítky 11 02 2014, EL OK, podil
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 23. 10. 2014 16:51.
Anotace
Background Compared with younger patients, older adults with acute myeloid leukemia (AML) generally have poorer survival outcomes and less benefit from clinical trials. A recent phase 3 trial demonstrated a trend toward improved overall survival (OS) with decitabine, a hypomethylating agent, compared with treatment choice of either cytarabine or supportive care (7.7 months, 95% CI: 6.2-9.2 vs 5.0 months, 95% CI: 4.3-6.3, respectively) in older adults with newly diagnosed AML. The current analyses investigated prognostic factors for outcomes in this trial and examined OS and responses in prespecified subgroups. Methods A multivariate Cox proportional hazards model was used to investigate effects of demographic and baseline characteristics, including age, sex, cytogenetic risk, AML type, ECOG Performance Status, geographic region, bone marrow blasts, platelets, and white blood cells on OS, based on mature data. Similar analyses were conducted with a logistic regression model to predict response rates. Prespecified subgroup analyses were performed for OS and response rates, also using mature data. Conclusion Response to decitabine in AML is associated with known prognostic factors related to both patient demographics and disease characteristics.
VytisknoutZobrazeno: 8. 8. 2022 14:47